Table 1:
Q1:40–64 n=309 | Q2:65–71 n=316 | Q3: 72–79 n=278 | Q4: 80–108 n=356 | P-Value | |
---|---|---|---|---|---|
Age, y | 75.0 ± 10.5 | 72.2 ± 10.1 | 70.6 ± 11.1 | 67.3 ± 11.0 | <0.001 |
Female, % | 35.3 | 31.0 | 34.9 | 26.1 | 0.030 |
Race, % | 0.084 | ||||
White | 87.1 | 91.1 | 91.7 | 89.0 | |
Black | 3.6 | 3.8 | 3.6 | 5.9 | |
Other | 9.4 | 5.1 | 4.7 | 5.1 | |
Avoid care due to cost, % | 4.9 | 6.3 | 6.9 | 6.2 | 0.770 |
High school education, % | 32.6 | 36.1 | 37.1 | 35.0 | 0.684 |
Heart rate, bpm | 68.1 ± 11.7 | 69.5 ± 11.7 | 73.2 ± 56.9 | 70.0 ± 11.1 | 0.182 |
Systolic BP, mmHg | 117.7 ± 16.3 | 124.4 ± 14.6 | 128.8 ± 13.2 | 139.1 ± 16.0 | <0.001 |
Heart Failure, % | 23.0 | 18.7 | 17.7 | 14.6 | 0.049 |
Current Smoker, % | 6.6 | 9.6 | 12.1 | 12.0 | 0.077 |
Hypertension,% | 77.0 | 80.1 | 79.8 | 81.7 | 0.509 |
Diabetes,% | 35.9 | 39.9 | 33.9 | 32.3 | 0.207 |
History of stroke/TIA, % | 7.4 | 7.6 | 7.9 | 7.6 | 0.996 |
History of MI, % | 34.0 | 35.4 | 45.1 | 39.3 | 0.027 |
Chronic kidney disease, % | 17.8 | 14.2 | 9.0 | 9.0 | <0.001 |
BMI, kg/m2 | 29.6 ± 6.5 | 30.5 ± 6.4 | 30.6 ± 6.5 | 31.3 ± 6.2 | 0.008 |
Calcium channel blocker, % | 26.9 | 26.9 | 21.6 | 27.5 | 0.320 |
Beta blocker, % | 77.3 | 81.0 | 82.7 | 76.4 | 0.166 |
ACE inhibitor, % | 35.3 | 40.2 | 38.8 | 37.4 | 0.623 |
ARB, % | 27.2 | 20.9 | 23.7 | 26.1 | 0.259 |
Diuretic, % | 51.1 | 42.7 | 36.3 | 34.6 | <0.001 |
Nitrate, % | 58.6 | 52.5 | 52.5 | 46.9 | 0.028 |
Ranolazine, % | 7.4 | 6.0 | 7.9 | 2.8 | 0.023 |
Any angina in past month, % | 37.0 | 33.7 | 29.9 | 30.3 | 0.198 |
SAQ Angina Frequency | 90.0 ±17.5 | 91.1± 15.1 | 92.6± 15.3 | 92.4 ± 15.3 | 0.143 |
Values presented as mean ± SD or %. Continuous variables compared using ANOVA. Categorical variables compared using Chi-square.
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; MI, myocardial infarction; SAQ, Seattle Angina Questionnaire; TIA, transient ischemic attack